WHAT IS CLAIMED IS:

1. A composition comprising a lysine demethylase (LSD) inhibitor and a protein kinase C theta (PKC-θ) inhibitor.

2. A composition according to claim 1, wherein the LSD inhibitor is a LSD1 inhibitor.

3. A composition according to claim 2, wherein the LSD1 inhibitor is a selective LSD1 inhibitor.

4. A composition according to any one of claims 1 to 3, wherein the PKC-θ inhibitor is a selective PKC-θ inhibitor.

5. A composition according to any one of claims 1 to 4, further comprising a pharmaceutically acceptable carrier.

6. A lysine demethylase (LSD) inhibitor and a protein kinase C theta (PKC-θ) inhibitor for use in treating or preventing a cancer or for use in inhibiting or preventing recurrence of a cancer.

7. A LSD inhibitor and PKC-θ inhibitor for use according to claim 6, wherein the cancer is a non-metastatic cancer.

8. A LSD inhibitor and PKC-θ inhibitor for use according to claim 6, wherein the cancer is a metastatic cancer.

9. A lysine demethylase (LSD) inhibitor and a protein kinase C theta (PKC-θ) inhibitor and a cancer therapy agent that inhibits the proliferation, survival or viability of the non-CSC tumor cell, for use in treating or preventing a cancer, wherein the LSD inhibitor, PKC-θ inhibitor and cancer therapeutic agent are formulated for concurrent administration.

10. A LSD inhibitor, PKC-θ inhibitor and cancer therapy agent for use according to claim 9, wherein the cancer therapy agent is selected from a chemotherapy agent, a hormone ablation therapy agent, a pro-apoptosis therapy agent and an immunotherapy agent.

11. A LSD inhibitor, PKC-θ inhibitor and cancer therapy agent for use according to claim 9 or claim 10, wherein the cancer therapy agent targets rapidly dividing cells or disrupts the cell cycle or cell division.

12. A LSD inhibitor and PKC-θ inhibitor for use according to any one of claim 6 to 8, or a LSD inhibitor, PKC-θ inhibitor and cancer therapy agent for use according to any one of claims 9 to 11, wherein the cancer is selected from breast, prostate, lung, bladder, pancreatic, colon, melanoma, liver or glioma cancer.

13. A LSD inhibitor and PKC-θ inhibitor for use according to any one of claim 6 to 8, or a LSD inhibitor, PKC-θ inhibitor and cancer therapy agent for use according to any one of claims 9 to 11, wherein the cancer is breast cancer.

14. A LSD inhibitor and PKC-θ inhibitor for use according to any one of claim 6 to 8, or a LSD inhibitor, PKC-θ inhibitor and cancer therapy agent for use according to any one of claims 9 to 11, wherein the cancer comprises a cancer stem cell (CSC).

15. A LSD inhibitor and PKC-θ inhibitor for use according to any one of claim 6 to 8, or a LSD inhibitor, PKC-θ inhibitor and cancer therapy agent for use according to any one of claims 9 to 11, wherein the CSC has impaired or abrogated expression of the pluripotent stem cell markers Oct4 or Sox2, or expresses one or both of those markers at a level or functional activity that is less than about 1/5 of the level or functional activity of those markers on a pluripotent stem cell.

16. Use of a lysine demethylase (LSD) inhibitor and a protein kinase C theta (PKC-θ) inhibitor in the manufacture of a medicament for treating or preventing a cancer or for inhibiting or preventing recurrence of a cancer.

17. The use according to claim 16, wherein the cancer is a non-metastatic cancer.

18. The use according to claim 16, wherein the cancer is a metastatic cancer.

19. Use of a lysine demethylase (LSD) inhibitor and a protein kinase C theta (PKC-θ) inhibitor and a cancer therapy agent that inhibits the proliferation, survival or viability of the non-CSC tumor cell, in the manufacture of a medicament for treating or preventing a cancer, wherein the LSD inhibitor, PKC-θ inhibitor and cancer therapeutic agent are formulated for concurrent administration.

20. The use according to claim 19, wherein the cancer therapy agent is selected from a chemotherapy agent, a hormone ablation therapy agent, a pro-apoptosis therapy agent and an immunotherapy agent.

21. The use according to claim 19 or claim 20, wherein the cancer therapy agent targets rapidly dividing cells or disrupts the cell cycle or cell division.

22. The use according to any one of claim 16 to 18, or the use according to any one of claims 19 to 21, wherein the cancer is selected from breast, prostate, lung, bladder, pancreatic, colon, melanoma, liver or glioma cancer.

23. The use according to any one of claim 16 to 18, or the use according to any one of claims 19 to 21, wherein the cancer is breast cancer.

24. The use according to any one of claim 16 to 18, or the use according to any one of claims 19 to 21, wherein the cancer comprises a cancer stem cell (CSC).

25. The use according to any one of claim 16 to 18, or the use according to any one of claims 19 to 21, wherein the CSC has impaired or abrogated expression of the pluripotent stem cell markers Oct4 or Sox2, or expresses one or both of those markers at a level or functional activity that is less than about 1/5 of the level or functional activity of those markers on a pluripotent stem cell.